CClinicalTrials.gg
CompletedNCT02811367Updated Oct 17, 2016

The HPV Self-test as a Test of Cure in Madagascar

An interventional study of HPV test in Human Papilloma Virus Infection and Cervical Intraepithelial Neoplasia Grade 2/3, sponsored by University Hospital, Geneva. Completed at 1 site in Madagascar. Open to female participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-17.

Sponsored by University Hospital, Geneva · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
117
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Female
01

Study summary

The purpose of this study is to find out whether Self-HPV may be an accurate method for the follow-up of women with a history of HPV infection.

Read the detailed description

The efficacy and the availability of cold coagulation render it a valuable technique for the treatment of precancerous lesions in low-resource settings. The Human Papillomavirus (HPV) test performed by women themselves (HPV self-test) could be an efficient method to assess the long-term risk of recurrent/persistent disease in women with a history of HPV infection and cervical intra-epithelial lesions grade 2 or higher (CIN2+).

A total of 443 HPV-positive women, aged 30-65 years, have been selected through a screening campaign conducted in Ambanja, Madagascar, between 2013 and 2015. Of these, 260 have been treated by cold coagulation, conisation or electrocauterization. A follow-up visit at 1-3 years after primary screening will be organized for all HPV-positive women detected at primary screening. Participants will perform an HPV self-test. A sample for cytology and HPV testing will also be collected by the physician. The goal of the study will be the histological search for CIN2+ lesions at one to three years after primary screening.

The investigators expect to see that Self-HPV may be an accurate method for the follow-up of women with a history of HPV infection.

02

Conditions studied

  • Human Papilloma Virus Infection
  • Cervical Intraepithelial Neoplasia Grade 2/3
03

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • women previously positive at HPV testing

Exclusion criteria

Exclusion Criteria:

  • pregnancy
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    HPV self-test

    Women will perform the HPV self-test.

    Device: HPV test

Interventions

  • DeviceHPV test

    Women will perform the HPV self-test and will also undergo a physician-performed HPV test.

05

What researchers measure

Primary outcomes

  1. Cervical intra-epithelial neoplasia grade 2 or worse

    Time frame: 4 months

06

Study locations

1 site
  • Saint Damien Medical Center
    Ambanja, Madagascar
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT02811367
Lead sponsor
University Hospital, Geneva
Responsible party
Prof. Patrick Petignat (Prof., University Hospital, Geneva) — Principal investigator
First posted
Jun 23, 2016
Start date
Jun 2016
Primary completion
Sep 2016
Completion
Sep 2016
Last update
Oct 17, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion